Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TL938 plus trastuzumab in HER2-positive advanced colorectal cancer
CTR20242861Phase 2Active
- Sponsor
- Taolue Biopharma
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tl938, trastuzumab, sponsored by Taolue Biopharma. Started May 2025; status: active.
02
Drugs
tl938trastuzumab
Beyond the preview
Go deeper on CTR20242861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242861.